Provided by Tiger Trade Technology Pte. Ltd.

Whitehawk Therapeutics, Inc.

3.50
+0.09002.64%
Volume:69.71K
Turnover:239.58K
Market Cap:199.53M
PE:-3.14
High:3.52
Open:3.37
Low:3.33
Close:3.41
52wk High:5.50
52wk Low:1.87
Shares:57.01M
Float Shares:28.74M
Volume Ratio:0.24
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1137
EPS(LYR):-0.3328
ROE:-44.98%
ROA:-28.70%
PB:1.09
PE(LYR):-10.52

Loading ...

Whitehawk Therapeutics announces $87.5M private placement

TIPRANKS
·
May 14

BRIEF-Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

Reuters
·
May 13

Whitehawk Therapeutics prices USD 87.5 million PIPE at USD 3.92 per share

Reuters
·
May 13

WhiteHawk Therapeutics Announces $87.5M Private Placement Equity Financing

THOMSON REUTERS
·
May 13

Natural gas mineral firm WhiteHawk reveals sevenfold revenue surge in US IPO filing

Reuters
·
May 11

Oppenheimer Sticks to Its Buy Rating for Whitehawk Therapeutics (WHWK)

TIPRANKS
·
May 08

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), Prime Medicine, Inc. (PRME) and Argenx Se (ARGX)

TIPRANKS
·
May 08

Whitehawk Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Whitehawk Therapeutics posts corporate deck outlining three-asset antibody-drug conjugate pipeline

Reuters
·
May 07

Whitehawk Q1 net loss turns to USD 22.2 million

Reuters
·
May 07

WhiteHawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

THOMSON REUTERS
·
May 07

Whitehawk Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
May 05

Whitehawk Therapeutics announces annual shareholder meeting

Reuters
·
Apr 29

Whitehawk Therapeutics' Antibody Drug Conjugates Indicate Potential Efficacy Against Cancer, Oppenheimer Says

MT Newswires Live
·
Apr 21

Oppenheimer Sticks to Their Buy Rating for Whitehawk Therapeutics (WHWK)

TIPRANKS
·
Apr 21

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Apr 21

Whitehawk Therapeutics publishes HWK-016 preclinical presentation on MUC16-targeting ADC

Reuters
·
Apr 20

Whitehawk announces presentation of new preclinical data across ADC portfolio

TIPRANKS
·
Apr 20

Whitehawk says Phase 1 trial for HWK-016 ADC in ovarian, endometrial cancers ongoing

Reuters
·
Apr 20

Whitehawk Therapeutics CEO joins Jones Trading Post-AACR virtual fireside chat

Reuters
·
Apr 17